<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30377674</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>14</Day>        </DateRevised>        <Article PubModel="Electronic-eCollection">            <Journal>                <ISSN IssnType="Electronic">2451-8654</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>12</Volume>                    <PubDate>                        <Year>2018</Year>                        <Month>Dec</Month>                    </PubDate>                </JournalIssue>                <Title>Contemporary clinical trials communications</Title>                <ISOAbbreviation>Contemp Clin Trials Commun</ISOAbbreviation>            </Journal>            <ArticleTitle>Improving adherence to endocrine hormonal therapy among breast cancer patients: Study protocol for a randomized controlled trial.</ArticleTitle>            <Pagination>                <MedlinePgn>109-115</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.conctc.2018.10.001</ELocationID>            <Abstract>                <AbstractText>Adjuvant endocrine hormonal therapy (EHT) is highly effective and appropriate for nearly all breast cancer patients with hormone receptor-positive tumors, which represent 75% of all breast cancer diagnoses. Long-term use of EHT reduces recurrence rates and nearly halves the risk of death during the second decade after diagnosis. Despite the proven benefits, about 33% of women receiving EHT do not take their medication as prescribed. This causes an increase in the risk for recurrence and death. To promote adherence to EHT among breast cancer patients, this study will develop and pilot-test an intervention consisting of 1) a bilingual, culturally tailored, personalized, interactive smartphone application (app); and 2) support from a patient navigator. The control group will receive usual care. This 2-group randomized control trial will recruit 120 breast cancer patients receiving EHT at the Mays Cancer Center at UT Health San Antonio. The two-year study will have 3-time assessments (baseline, 3 and 6 months). This theory-based intervention will empower patients' self-monitoring and management. It will facilitate patient education, identification/reporting of side effects, delivery of self-care advice, and simplify communication between the patient and the oncology team. The ultimate goal of this innovative multi-communication intervention is to improve overall survival and life expectancy, enhance quality of life, reduce recurrence, and decrease healthcare cost. The anticipated outcome is a scalable, evidence-based, and easily disseminated intervention with potentially broad use to patients using EHT and other oral anticancer agents.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Chalela</LastName>                    <ForeName>P</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>Institute for Health Promotion Research, UT Health San Antonio, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Munoz</LastName>                    <ForeName>E</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Institute for Health Promotion Research, UT Health San Antonio, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Inupakutika</LastName>                    <ForeName>D</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>University of Texas at San Antonio, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kaghyan</LastName>                    <ForeName>S</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>University of Texas at San Antonio, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Akopian</LastName>                    <ForeName>D</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>University of Texas at San Antonio, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kaklamani</LastName>                    <ForeName>V</ForeName>                    <Initials>V</Initials>                    <AffiliationInfo>                        <Affiliation>Mays Cancer Center, UT Health San Antonio, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lathrop</LastName>                    <ForeName>K</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>Mays Cancer Center, UT Health San Antonio, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ramirez</LastName>                    <ForeName>A</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Institute for Health Promotion Research, UT Health San Antonio, USA.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <GrantID>P30 CA054174</GrantID>                    <Acronym>CA</Acronym>                    <Agency>NCI NIH HHS</Agency>                    <Country>United States</Country>                </Grant>                <Grant>                    <GrantID>U54 CA153511</GrantID>                    <Acronym>CA</Acronym>                    <Agency>NCI NIH HHS</Agency>                    <Country>United States</Country>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>17</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Netherlands</Country>            <MedlineTA>Contemp Clin Trials Commun</MedlineTA>            <NlmUniqueID>101671157</NlmUniqueID>            <ISSNLinking>2451-8654</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Pharmacy (Basel). 2018 Mar 08;6(1):null</RefSource>                <PMID Version="1">29518017</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Support Care Cancer. 2014 Apr;22(4):937-45</RefSource>                <PMID Version="1">24271937</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Biomed Inform. 2009 Apr;42(2):377-81</RefSource>                <PMID Version="1">18929686</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Breast Cancer. 2014 Dec;14(6):460-467.e2</RefSource>                <PMID Version="1">24981234</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Am J Geriatr Pharmacother. 2010 Apr;8(2):136-45</RefSource>                <PMID Version="1">20439063</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2013 Feb;137(3):829-36</RefSource>                <PMID Version="1">23263740</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>CA Cancer J Clin. 2011 Jul-Aug;61(4):237-49</RefSource>                <PMID Version="1">21659419</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Cancer Surviv. 2014 Sep;8(3):521-31</RefSource>                <PMID Version="1">24986227</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Epidemiol. 2014 Jun;38(3):214-26</RefSource>                <PMID Version="1">24768601</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Springerplus. 2013 Dec;2(1):84</RefSource>                <PMID Version="1">23519779</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncol Nurs Forum. 2010 Sep;37(5):E349-58</RefSource>                <PMID Version="1">20797943</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Pharmacotherapy. 2014 May;34(5):481-94</RefSource>                <PMID Version="1">24877187</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2012 Apr;23(4):882-90</RefSource>                <PMID Version="1">21788360</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Affect Disord. 2009 Apr;114(1-3):163-73</RefSource>                <PMID Version="1">18752852</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer. 2013 Apr 1;119(7):1298-305</RefSource>                <PMID Version="1">23233265</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Cancer Care (Engl). 2012 Jan;21(1):10-9</RefSource>                <PMID Version="1">22004071</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2010 Aug 10;28(23):3784-96</RefSource>                <PMID Version="1">20625130</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Br J Cancer. 2013 Sep 3;109(5):1172-80</RefSource>                <PMID Version="1">23949153</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Womens Health (Larchmt). 2015 Feb;24(2):138-43</RefSource>                <PMID Version="1">25522246</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2011 Apr;126(2):529-37</RefSource>                <PMID Version="1">20803066</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Am J Med Qual. 2017 Jul/Aug;32(4):406-413</RefSource>                <PMID Version="1">27357461</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 1993 Mar;11(3):570-9</RefSource>                <PMID Version="1">8445433</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Am J Public Health. 2015 Jul;105 Suppl 3:e4-e15</RefSource>                <PMID Version="1">25905855</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast. 2015 Oct;24(5):630-6</RefSource>                <PMID Version="1">26189978</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Arch Intern Med. 2006 May 22;166(10):1092-7</RefSource>                <PMID Version="1">16717171</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Hypertens (Greenwich). 2008 May;10(5):348-54</RefSource>                <PMID Version="1">18453793</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2018 Feb;167(3):615-633</RefSource>                <PMID Version="1">29110151</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Health Psychol. 2004 Mar;23(2):207-18</RefSource>                <PMID Version="1">15008666</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Med. 2012 Dec;1(3):318-27</RefSource>                <PMID Version="1">23342281</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin J Oncol Nurs. 2008 Apr;12(2):213-21</RefSource>                <PMID Version="1">18390458</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2008 Feb 1;26(4):556-62</RefSource>                <PMID Version="1">18180462</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet. 2013 Mar 9;381(9869):805-16</RefSource>                <PMID Version="1">23219286</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2012 Mar 20;30(9):936-42</RefSource>                <PMID Version="1">22331951</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ir J Med Sci. 2016 May;185(2):383-92</RefSource>                <PMID Version="1">25971465</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Psychol Methods. 2013 Jun;18(2):137-50</RefSource>                <PMID Version="1">23379553</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2011 Jan;125(1):191-200</RefSource>                <PMID Version="1">20495864</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Br J Cancer. 2013 Apr 16;108(7):1515-24</RefSource>                <PMID Version="1">23519057</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2009 Mar;20(3):431-6</RefSource>                <PMID Version="1">19150950</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Transl Behav Med. 2014 Dec;4(4):372-81</RefSource>                <PMID Version="1">25584086</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Am Med Inform Assoc. 2017 Sep 1;24(5):1024-1035</RefSource>                <PMID Version="1">28379397</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 2005 Oct 27;353(17):1784-92</RefSource>                <PMID Version="1">16251534</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Patient Educ Couns. 2005 Oct;59(1):97-102</RefSource>                <PMID Version="1">16198223</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Cancer Res Clin Oncol. 2015 Jan;141(1):55-60</RefSource>                <PMID Version="1">25085010</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Cancer. 2012 Sep;48(13):1939-46</RefSource>                <PMID Version="1">22464016</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Oncol Pract. 2012 Nov;8(6):e149-57</RefSource>                <PMID Version="1">23598850</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Epidemiol Biomarkers Prev. 2012 Oct;21(10):1639-44</RefSource>                <PMID Version="1">23045538</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Adherence</Keyword>            <Keyword MajorTopicYN="N">Breast cancer</Keyword>            <Keyword MajorTopicYN="N">Endocrine hormone therapy</Keyword>            <Keyword MajorTopicYN="N">Patient navigation</Keyword>            <Keyword MajorTopicYN="N">Smartphone app</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>06</Month>                <Day>07</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>09</Month>                <Day>20</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>10</Month>                <Day>16</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>11</Month>                <Day>1</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>11</Month>                <Day>1</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>11</Month>                <Day>1</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30377674</ArticleId>            <ArticleId IdType="doi">10.1016/j.conctc.2018.10.001</ArticleId>            <ArticleId IdType="pii">S2451-8654(18)30078-4</ArticleId>            <ArticleId IdType="pmc">PMC6202663</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>